CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 60 enrolled
Drug / intervention
Clopidogrel +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00140465
NCT00140465Phase 4Completed
CompareCT.gov

A Double-Blind, Randomized Comparison Between Two Different Clopidogrel Maintenance Doses After Percutaneous Coronary Intervention (ISAR-CHOICE-2)

Deutsches Herzzentrum Muenchen·interventional·Posted Sep 1, 2005·Updated Nov 14, 2007

In Brief

A Phase 4 clinical trial evaluating Clopidogrel for Coronary Disease. Completed, enrolled 60 participants across 1 site.

Detailed Summary

The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronary Disease
CountriesGermany
CollaboratorsTechnical University of Munich

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 1, 2005
Enrollment StartOct 1, 2004
Study CompletionJul 1, 2005
TodayJul 2, 2026
Posted 20.8 years ago

Interventions

Clopidogreldrug

after PCI

Clopidogreldrug

after PCI